Abbvie INC DEF 14A proxy statements

AbbVie's latest proxy statement highlights robust 2025 financial performance, key governance proposals including eliminating supermajority voting, and director elections for the upcoming 2026 Annual Meeting.

AbbVie Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 9, 2025, featuring key proposals including the election of directors, ratification of the company's accounting firm, executive compensation, and voting amendments.

AbbVie's 2025 proxy statement outlines key governance changes, including a CEO transition and a proposal to eliminate supermajority voting, alongside details on executive compensation and director nominees.

AbbVie Inc. has scheduled its Annual Meeting for May 3, 2024, and is soliciting shareholder votes on key proposals, including the election of directors, ratification of auditors, executive compensation, and amendments to corporate governance.

AbbVie's 2024 proxy statement details key proposals for the annual meeting, including director elections, auditor ratification, executive compensation, and governance changes.